

Pharmacy Medical Necessity Guidelines: Daliresp® (roflumilast)

Effective: January 14, 2020

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
<p>These pharmacy medical necessity guidelines apply to the following:</p> <p>Commercial Products</p> <input type="checkbox"/> Tufts Health Plan Commercial products – large group plans <input type="checkbox"/> Tufts Health Plan Commercial products – small group and individual plans <input type="checkbox"/> Tufts Health Freedom Plan products – large group plans <input type="checkbox"/> Tufts Health Freedom Plan products – small group plans <ul style="list-style-type: none"> CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization <p>Tufts Health Public Plans Products</p> <input type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) <input checked="" type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans <input type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan		<p>Fax Numbers: RXUM: 617.673.0988</p>	

Note: This guideline does not apply to Medicare Members (includes dual eligible Members).

OVERVIEW

FDA-APPROVED INDICATIONS

Roflumilast (Daliresp®) is a phosphodiesterase-4 (PDE4) inhibitor indicated as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Its principal action is to reduce inflammation by inhibiting the breakdown of intracellular cyclic AMP. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD guidelines consider roflumilast an add-on option in patients treated with a long-acting beta-agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid who are still having exacerbations with a forced expiratory volume in the first second (FEV₁) < 50% predicted and chronic bronchitis.

Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

The Tufts Health Together PDL status is as follows:

Generic Name	Brand Name	PDL Status
Roflumilast	Daliresp	PA

COVERAGE GUIDELINES

The plan may authorize coverage of Daliresp® (roflumilast) for Members when the following criteria are met and limitations do not apply:

- The Member has the diagnosis of chronic obstructive pulmonary disease (COPD) or COPD associated with chronic bronchitis
- AND**
- Member is new to the Plan and has been stabilized on Daliresp® for the treatment of COPD
- OR**
- The Member has tried and failed therapy with the combination of a long-acting bronchodilator (long-acting beta agonist or a long-acting anticholinergic) and an inhaled corticosteroid

LIMITATIONS

None

CODES

None

REFERENCES

- Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca; January 2018.
- FDA approves new drug to treat chronic obstructive pulmonary disease. [Access June 2011]. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm>

3. Calverley P, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomized clinical trials. *Lancet* 2009; 374: 685-94.
4. Fabbri L, et al. Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomized clinical trials. *Lancet* 2009; 374: 695-703.
5. Mill E, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. *Clin Epidemiol.* 2011;3:107-129.
6. Rutten-Van Mólken, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. [Abstract] *Pharmacoeconomics* 2007;25(8):695-711.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed December 27, 2019.

APPROVAL HISTORY

February 10, 2015: Reviewed by Pharmacy & Therapeutics Committee; approval limited to one year.

Subsequent endorsement date(s) and changes made:

1. September 16, 2015: Approval duration approved for life of plan.
2. January 1, 2016: Administrative change to rebranded template.
3. January 12, 2016: No changes.
4. January 10, 2017: Added exception language for Members new to the plan and stable on Daliresp prior to enrollment. Updated criteria to require trial and failure with a long-acting bronchodilator and an inhaled corticosteroid.
5. May 9, 2017: Administrative update, Adding Tufts Health RITogether to the template.
6. January 9, 2018: No changes.
7. January 8, 2019: Administrative changes made to template.
8. July 9, 2019: Effective October 1, 2019, updated MNG to indicate that Daliresp will be moving from Step Therapy to Prior Authorization required.
9. January 14, 2020: No changes.

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

[Provider Services](#)